Skip to main content

Online First

An important and inspiring documentary on Dr Carl June’s quest to cure cancer, CAR T-cell therapy, and his first pediatric patient. Read More ›

On September 26, 2023, the FDA approved a new indication for bosutinib (Bosulif; Pfizer), a tyrosine kinase inhibitor, for the treatment of chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia in pediatric patients aged ≥1 years who are newly diagnosed or who are intolerant of or whose disease is resistant to previous therapy. A new capsule dosage form was also FDA approved, in 50-mg and 100-mg strengths; bosutinib was previously available only in 100-mg, 400-mg, and 500-mg tablet forms. The FDA granted this approval priority review and an orphan drug designation. Read More ›

On September 14, 2023, the FDA approved new and updated indications for temozolomide (Temodar; Merck) capsules and injection, an alkylating drug, including for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma, and for the treatment of adults with refractory anaplastic astrocytoma. The previously approved indication for the treatment of adults with newly diagnosed glioblastoma, concomitant with radiotherapy, then as maintenance treatment, remains unchanged. Read More ›

Peer-to-peer (PTP) support is an important aspect of nonprofessional patient care that improves cancer-specific quality of life. However, PTP research is sorely lacking, with very few randomized controlled trials being conducted in this space, as well as a lack of standardized quality parameters for what constitutes successful and efficient PTP support, according to newly published research. Read More ›